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N
IDDM is a multifactorial disease that is increasingly common in adults in most populations (1). The familial character of NIDDM has long been suspected and was properly documented by several studies early in the 20th century (2-5). In the past 2 decades, twin studies and family studies have provided stro n g evidence for a genetic component in NIDDM. Concordance rate estimates for monozygotic twins range from 34 to 100% and are approximately two times higher than those for dizygotic twins (6-9). Family studies suggest a three-to fourf o l d i n c reased risk to fir s t -d e g ree relatives of individuals with NIDDM compared with the general population (10).
Because of the likely etiologic heterogeneity of NIDDM, it may be useful to study i n t e rmediate quantitative traits that pre d i spose individuals to diabetes in order to identify the diabetes genes (11). Familial a g g regation of insulin resistance has been shown in several studies (12-16), and a g g regation has recently been demonstrated for acute insulin secre t o ry response (17). Although it remains uncertain whether the p r i m a ry defect leading to NIDDM is peripheral insulin resistance or a relative decre a s e in insulin secretion, most NIDDM patients have both defects. Thus, eff o rts to map these and other NIDDM-related quantitative traits have the potential to increase our understanding of the genetics of NIDDM.
Until re c e n t l y, the search for genes for NIDDM has focused on population association and linkage studies using the candidate-gene approach. Although association or linkage has been re p o rted for some candidate genes, the results from these studies have not elucidated diabetes genes and instead indicate that a systematic search of the entire genome is warranted. Perf o rm i n g a genome search now is propitious because i n c reasingly dense and more complete genetic maps have become available, methods of genotyping have become more eff icient, and linkage analysis techniques suited to the study of complex diseases continue to be developed (11).
To map the genes for NIDDM and NIDDM-associated traits such as acute
Mapping genes for NIDDM insulin response and insulin resistance, we have chosen the Finnish population as the t a rget for our study. In this paper, we describe the rationale, design, and sample characteristics of the Finland-United States Investigation of NIDDM Genetics (FUSION) s t u d y.
RESEARCH DESIGN AND M E T H O D S
Family ascertainment criteria Relatives of individuals who were diagnosed with NIDDM at an early age have a higher disease risk than relatives of individuals with a later onset of disease (18). However, t h e re is a relatively greater risk of IDDM among the younger age-groups. There f o re , to maximize the genetic component while minimizing the likelihood of identifying subjects with IDDM, we ascert a i n e d p robands in whom diabetes was diagnosed between 35 and 60 years of age. A given family was eligible for participation in the FUSION study if 1) the proband or another a ffected sibling was diagnosed with NIDDM between 35 and 60 years of age, 2) there was no history of IDDM in fir s t -d e g ree re latives, 3) the proband had one or more full siblings diagnosed with NIDDM at any age, and 4) at least one parent was appare n t l y nondiabetic, with pre f e rence given to families with living parents or parents who had lived a long life without known diabetes. The last criterion was included to minimize b i l i n e a l i t y. In this paper, we use the term index case to indicate the first proband or a ffected sibling in each family who met our study inclusion criteria.
Sources and types of families
T h e re are approximately 150,000 known NIDDM patients in Finland. The pro b a n d s in the FUSION study were identified primarily from the National Hospital Disc h a rge Registry (NHDR), which includes re c o rds since 1970 of all hospitalized patients with diabetes, and from pre v i o u s studies carried out by the National Public Health Institute in Finland. From the NHDR, we identified all patients who were hospitalized with a diagnosis of NIDDM in Finland during 1987-1993. A total of 33,029 potential pro b a n d s w e re initially identified in 1994, 29,807 of them from the NHDR. A total of 22,312 s c reening questionnaires were sent to the NIDDM patients living relatively close to one of the 21 clinics we established for this s t u d y. The patients were also sent a short description of study eligibility criteria, including our minimum re q u i rement of a diabetic sib pair. A total of 9,626 individuals re t u rned the screening questionnaire. In addition, 14 eligible families voluntarily contacted us and were included in the study.
Families in the FUSION study were c l a s s i fied as nuclear or extended. In the nuclear families, all the affected siblings and any living parents were studied. At least one affected sib pair (ASP) was re q u i red in each family. In the extended families, in addition to the nuclear family members, we studied a nondiabetic spouse and at least two offspring of an affected sibling, fulfilling the proband criteria described above.
Control subjects
The primary purpose of the control subjects in the FUSION study was to pro v i d e allele frequency estimates in unaff e c t e d individuals for comparison with aff e c t e d individuals. All our control subjects were b o rn in the year 1925 and had been examined with oral glucose tolerance tests ( O G T Ts) in 1990 as part of the South Finland Aging Study (19). Those who had n o rmoglycemic OGTT values by the Wo r l d Health Org a n i z a t i o n ' s (WHO) criteria were given a second OGTT as part of the FUSION study in 1995, and the 248 individuals with normal glucose tolerance a c c o rding to both OGTTs were included as c o n t rol subjects for the FUSION study.
Diabetes status
The diagnosis of diabetes was accepted if an individual was receiving drug treatment for diabetes or if the blood glucose values obtained from the medical re c o rds met current WHO criteria (20). Fasting blood glucose was determined in all individuals at the FUSION examination. If patients were t reated with diet alone and fasting blood glucose was 7.0 mmol/l, the diagnosis of diabetes was confirmed by OGTT. The age at diagnosis of NIDDM was based on selfre p o rted information. The inferred diabetes status of parents was based primarily on i n f o rmation re p o rted by the affected siblings because nearly all their parents were d e c e a s e d .
Cases of probable IDDM were identified to exclude them from future analyses. An individual was classified as having p robable adult-onset IDDM if 1) insulin t reatment was started within 10 years of disease diagnosis, autoantibodies to GAD w e re detected, and the fasting C-peptide was 0.30 nmol/l; or if 2) insulin tre a tment was started within 4 years of diagnosis and the fasting C-peptide was 0 . 3 0 nmol/l. Medical re c o rd review was carr i e d out for all affected individuals whose Cpeptide was 0.50 nmol/l, who had antibodies to GAD, or who were treated with insulin and for whom C-peptide and/or GAD antibody samples were not assayed in the FUSION study to confirm their age of diagnosis and the age when insulin tre a tment was start e d .
Study clinics and examinations
The FUSION study was carried out in 21 cities distributed throughout much of Finland. The study nurses from each clinic attended a 1-week training seminar in Helsinki. Blood collection and all clinical m e a s u rements were carefully standard i z e d .
All study subjects underwent a scre e ning examination during a single visit. In addition, nondiabetic spouses and offspring re t u rned for a frequently sampled intravenous glucose tolerance test (FSIGT) during a second visit. At the scre e n i n g examination, blood pre s s u re, pulse, weight, height, and waist and hip circ u m f e re n c e s w e re measured on all participating family members and control subjects. Also, data on medical and lifestyle history, medication, current health status, physical activity, diet, smoking history, alcohol consumption, gestational medical history, and birt h weight were collected from all family members and control subjects.
Blood samples for DNA, fasting glucose and insulin, and serum lipids were drawn for all participating family members. In addition, OGTTs were carried out in nondiabetic family members. OGTTs w e re perf o rmed according to WHO criteria (75-g oral load of glucose). Serum C-peptide and autoantibodies to GAD were assayed in the affected family members. An overnight urine sample was collected f rom each diabetic family member to assess u r i n a ry albumin-to-creatinine ratio.
To l b u t a m i d e -m o d i fied FSIGTs were p e rf o rmed in nondiabetic spouses and nondiabetic offspring during a second visit in six clinics. The reduced sampling pro t ocol, in which 14 blood samples for glucose and insulin were collected over the course of a 3-h test (21), was employed. FSIGT data were analyzed, using the Minimal Model method (22), to derive quantitative m e a s u res of insulin sensitivity (S I ) and glucose effectiveness (S G ). Insulin secre t i o n was assessed as the acute insulin re s p o n s e 
Assays
Blood glucose concentration was initially m e a s u red at the study clinic using a glucose monitoring device (One Touch; LifeScan, Milpitas, CA). Plasma glucose, plasma insulin, and serum C-peptide samples were f rozen and shipped on dry ice to the central l a b o r a t o ry at the University of Southern Cali f o rnia in Los Angeles, California, for measu rement. Plasma glucose was measured on an autoanalyzer (YSI-2700; YSI, Ye l l o w Springs, OH) using the glucose oxidase method. Interassay coefficients of variation (CVs) were 2.9 and 2.3% for the low and high quality control (QC) pools, re s p e c t i v e l y. The correlation between One Touch and plasma glucose values was 0.94 and 0.96 for fasting glucose and postload glucose values, re s p e c t i v e l y. Plasma insulin was measure d by radioimmunoassay (RIA) using dextranc h a rcoal separation (24) . Antibody and tracer for the insulin RIA were purc h a s e d f rom Novo Nordisk (Bagsvaerd, Denmark). Interassay CVs were 11 and 13% for low and high QC pools, re s p e c t i v e l y. Serum Cpeptide was determined by using a kit purchased from Linco (St. Charles, MO) with interassay CVs of 14 and 5% for low and high QC pools, re s p e c t i v e l y.
Autoantibodies to GAD were measure d at the University of Washington in Seattle, Washington, by fluid-phase immunoprecipitation assay (25) using re c o m b i n a n t human GAD65 radiolabeled by in vitro translation (TNT; Promega, Madison, WI) in the presence of [ 3 5 S]methionine (Amersham, Arlington Heights, IL) (26) . The assay had high sensitivity and 100% specificity in an i n t e rnational GAD antibody workshop (27) and an interassay CV of 15%.
S e rum total and HDL cholesterol and triglycerides were determined in Helsinki f rom fresh samples using an enzymatic assay method (CHOD-PAP; Monotest; Boehringer Mannheim, Indianapolis, IN). The interassay CVs for total cholesterol, HDL cholestero l , and triglycerides were 1.2, 2.2, and 1.6%, re s p e c t i v e l y. Urine creatinine and albumin concentrations were also measured at the National Public Health Institute in Helsinki. The creatinine in urine was determ i n e d using the method of Jaffe (28), and the urin a ry albumin concentration was determ i n e d by the immunoturbidometric method, using reagents from Roche (Montclair, NJ) (29). Interassay CVs for urine creatinine and albumin were 2.4 and 5.1%, re s p e c t i v e l y. DNA was isolated from 30 ml of fre s h whole blood in EDTA using the Purgene D-50K DNA isolation kit (Gentra Systems, Plymouth, MN) at the National Public Health Institute. The isolated samples were f rozen and shipped on dry ice to the National Human Genome Research Institute in Bethesda, Mary l a n d .
Genotyping
The genetic markers being used for genetic mapping in the FUSION study are modified ABI sets (Applied Biosystems Division of Perkin-Elmer, Foster City, CA) consisting of approximately 365 dinucleotide re p e a t s divided into 28 panels, each of which contains 7 to 19 markers generating a 10-cent i m o rgan (cM) average density map. I n c o rrect genotypes can give rise to infla t e d map lengths and reduced power to detect linkage. Thus, a genotyping system that has a low frequency of errors is a part i c ularly important tool in the study of complex diseases, in which gene effects may often be weak. Because the commercially based softw a re available from ABI is not very eff i c i e n t at automatically adjusting for gel-to-gel variation in allele sizing, or for allele calling ("binning"), we developed software to do these tasks automatically. In addition, we optimized our genotyping system for precise sizing and binning of alleles (30) . The automation also allows us to run a series of i n t e rnal checks to improve the binning accuracy and re p ro d u c i b i l i t y. The blinded p resence of samples in duplicate allowed us to estimate a genotype-specific error rate of 0.034% (2 of 5,846) for the last 64 markers typed in our laboratory.
Because of previous findings suggesting an association between HLA haplotypes and NIDDM, HLA-A, C, B, Bw, DR a n d D Q genotypes were also determ i n e d s e rologically using 180 HLA antisera (120 class I and 60 class II) (31) in 110 extended families in Helsinki.
Statistical analysis plan
The variety of phenotypic data, together with the uncertain etiology of NIDDM and its associated quantitative traits, re q u i res a multifaceted statistical analysis strategy. In the initial phase of genome screening for NIDDM, we will depend primarily on m o d e -o f -i n h e r i t a n c e -f ree methods of linkage analysis that compare estimated allele sharing identical by descent (IBD) in the ASPs to expectations under the hypothesis that no disease locus is present (32) (33) (34) . By parameterizing our models in terms of p robability of IBD sharing in the ASPs, we will be able both to search for linkage and to build exclusion maps of regions that appear unlikely to harbor NIDDM genes of s p e c i fied levels of genetic effect. Similar a p p roaches can be taken for the NIDDMassociated quantitative traits using a re g re ssion or variance components framework ( 3 5 , 3 6 ) .
In the initial genome scan, we will follow up even rather modest suggestions of linkage by typing additional markers in the region. Our simulations (32) suggest that following up logarithm of odds (LOD) s c o res even as low as 1.0 is not expected to result in more than about 10 false-positive findings in a genome scan of 300-400 markers and provides good power to detect loci of even modest effect. For regions ident i fied as likely to harbor a disease gene, we also will employ mode-of-inheritance-based methods of linkage analysis as well as combined segregation and linkage analysis in hopes of more accurately assessing the existence and the effect of the putative disease loci. In addition, we will emphasize linkage disequilibrium mapping as a complement a ry strategy of disease gene localization, p a rticularly once initial evidence for linkage is obtained.
R E S U LT S
Family ascertainment Among the 9,626 respondents to the s c reening questionnaire, there were 1,835 potential probands with onset of diabetes between 35 and 60 years of age who had at least one affected sibling and not both parents known to be diabetic. These potential p robands were ranked according to their family information, with pre f e rence given to families with evidence of at least one nondiabetic parent and multiple earlyonset affected siblings. A total of 1,382 potential probands living near one of the 21 FUSION study clinics were contacted by phone to confirm their eligibility and willingness to participate. Of these, 470 potential probands or their affected siblings were unable or unwilling to part i c ipate. An additional 286 diabetic patients w e re found be ineligible during the fir s t i n t e rv i e w. Thus, from the list of potential p robands and volunteers who contacted us, we enrolled 640 affected individuals f rom 577 separate families in the FUSION s t u d y. In addition, three families were e n rolled in the study after the index case refused to part i c i p a t e .
Characteristics of the study subjects All index cases, siblings, and control subjects were born in Finland. Of the 577 studied index cases, diabetes status could not be confirmed in 7 individuals by fasting plasma glucose, OGTT, or review of the medical re c o rds. In addition, 20 index cases were classified as having pro b a b l e adult-onset IDDM, leaving 550 index cases meeting FUSION study criteria for NIDDM ( Table 1) . A total of 733 siblings of the index cases with self-re p o rted history of NIDDM were studied, and 638 of these siblings met FUSION study criteria for NIDDM. A total of 2,376 individuals were examined in the FUSION study (Table 1) .
In the FUSION study, we have investigated a total of 580 Finnish families, ranging in size from 1 to 13 members. Of this total, 533 families have at least two siblings a ffected with diabetes, resulting in a total of 795 ASPs (Table 2 ). In 495 of these 533 families, no cases of probable adult-onset IDDM were identified among the individuals examined in the FUSION study or among the fir s t -d e g ree relatives of the index cases or affected siblings, resulting in a total of 740 ASPs.
O ffspring were studied in 210 extended families, and FSIGTs were carr i e d out in 79% of these families. Altogether, 602 FSIGTs were successfully done for n o n a ffected family members in families with no IDDM cases. An FSIGT was completed for at least two nondiabetic off s p r i n g in 156 families with a nondiabetic spouse c o n firmed by OGTT (Table 2) .
Of the affected index cases and aff e c t e d siblings, 55 and 45% were men, re s p e ct i v e l y. The mean age of onset of diabetes was 49 years (range, 25-69) in male index cases and 51 years (30-72) in female index cases. The age of onset for affected siblings was 53 (29-74) and 54 (22-80) years in men and women, respectively (Table 3) .
Of the index cases and siblings with NIDDM, 12% were treated with diet alone, 46% with oral hypoglycemic agents (OHAs), 21% with insulin alone, and 20% with a combination of insulin and OHAs.
The distribution of treatment modes corresponds well with that seen in Finnish diabetes clinics in general (37) .
T h e re were no notable diff e rences in the means of the weight-related variables between affected index cases and siblings within either sex (Table 3) . Of the male index cases and siblings, 40% were clearly o v e rweight (BMI 30 kg/m 2 ); 51% of the female index cases and 44% of the female siblings with NIDDM were overw e i g h t .
The control subjects were leaner: only 18% of men and 24% of women were clearly o v e rw e i g h t .
Of the index cases and their aff e c t e d siblings, 7% had a fasting C-peptide value of 0.30 nmol/l. Of these diabetic subjects, 42% were classified as having pro b able adult-onset IDDM. Antibodies to GAD w e re detected in 3.2% of the affected index cases and in 4.1% of the affected siblings. After excluding the subjects classified as having probable IDDM, 10 (1.9%) of the 517 affected index cases and 13 (2.2%) of the 594 affected siblings showed GAD antibody positivity. In normoglycemic contro l subjects, GAD autoantibodies were detected in 2 (1.7%) of the 120 studied individuals. The mean fasting C-peptide values between 1.5 and 1.7 nmol/l for affected index cases and siblings (Table 4) , re s p e c t i v e l y, are typical for individuals with NIDDM.
T h e re were no notable diff e re n c e s between index cases and siblings in seru m lipid and blood pre s s u re values (Table 5) . HDL cholesterol levels were considerably h i g h e r, and triglyceride levels were lower, in control subjects than in affected individuals. Based on the questionnaire data, 60% of the male index cases and 51% of male
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Mapping genes for NIDDM Data are n. Control subjects were not included in these data. *Three index cases refused to participate after the family was enrolled; additional affected siblings met study criteria for proband in these families. †In families with no IDDM cases.
Valle and Associates
a ffected siblings had hypertension; 25% of the male control subjects re p o rted hypertension. In women, the contrast between a ffected individuals and control subjects was even greater: 65 and 60 vs. 24% for female index cases, affected siblings, and c o n t rol subjects, re s p e c t i v e l y.
The Minimal Model-derived FSIGT values for nondiabetic spouses and offspring are shown in Table 6 . Nondiabetic women were generally more insulin sensitive than nondiabetic men. In men, this finding was partly compensated for by a m o re robust acute insulin response. Howe v e r, the mean disposition index re m a i n e d higher in females than in males. Also, the n o n a ffected spouses were more insulin resistant than their off s p r i n g . Mapping genes for NIDDM such as NIDDM, careful attention should be paid to all elements of study design. These elements include selection of the study population, ascertainment and exclusion criteria for probands and families, and the choice of phenotypes and genetic markers for study. Curre n t l y, there are several ongoing eff o rts to map the susceptibility genes for NIDDM using the whole genome searc h a p p roach (38-42) and many others using the candidate-gene approach. To perm i t valid comparison of results from diff e re n t studies and to assess the meaning of consistency or inconsistency of these re s u l t s , p roper understanding of study design, study methods, and family samples is of critical importance. In this re p o rt, we have described the sampling design and study methods we are using, and the sample of families obtained, in the FUSION study.
C O N C L U S I O N S -In a study of the d e t e rminants of a complex genetic disease

Advantages and relevance of a genetic study of NIDDM in Finland
T h e re are several advantages in using a Finnish population for carrying out genetic studies. The vast majority of Finland' s 5.1 million inhabitants belong linguistically and ethnically to the Finno-Ugrian ethnic gro u p with some admixture with the Swedish population in the coastal areas of the count ry. Finns are closely related to other populations of nort h e rn Europe (43) , and it has been estimated that the bottleneck in the Finnish population dates back 4,000 years (44) . During the first centuries after the end of migration in about A.D. 800, linguistic, geographic, and cultural barriers kept the Finns isolated from the surrounding are a s (45) . This small founding population and relative homogeneity increases the likelihood that individual genes predisposing to NIDDM can be identified, as has been demonstrated for genes responsible for several monogenic here d i t a ry diseases (46) (47) (48) . Relative genetic homogeneity is likely to have resulted in fewer NIDDM genes segregating than in outbred populations such as those of the U.S. or the U.K., so that individual NIDDM-susceptibility genes should be easier to detect. This distinction is important, because the detection of genes for a complex disease generally re q u i res larg e samples of families, and the power to detect linkage is inversely related to the magnitude of the effect of the gene on disease risk. NIDDM in Finland is clinically similar to NIDDM in other European populations, and the prevalence of NIDDM in Finland is similar to that of most other European populations (49) . Thus, it is reasonable to expect that NIDDM susceptibility genes identifie d Affected fathers 4.6 ± 1.7 (5.6) 1.12 ± 0.36 (1.11) 1.1 ± 0.6 (1. Data are means ± SD (median). AIR G , acute insulin response to glucose; S G , glucose effectiveness; S I , insulin sensitivity.
in Finns will play a role in NIDDM risk in non-Finnish populations as well.
Previous studies
Until re c e n t l y, genetic studies of NIDDM have focused on the candidate-gene a p p roach. Such studies in Finland have included investigations of the HLA system on chromosome 6 (50), and genes for glycogen synthase (51), glucokinase (52, 53) , hexokinase II (54,55), GLUT4 (56), fatty acid binding protein (57), a p o l i p o p rotein D (58), the insulin re c e p t o r substrate 1 (59, 60) , and the 3 -a d re n e rg i c receptor (61) . Except for a very signific a n t association between certain HLA haplotypes and NIDDM (50), these studies have not revealed major positive fin d i n g s . R e c e n t l y, results from two whole genome searches for NIDDM have been re p o rted, one based on 330 Mexican-American ASP families from Starr County, Te x a s (38), the second on 26 moderate-sized Finnish families from western Finland (39). Hanis et al. (38) re p o rted evidence for linkage in several chromosomal regions, with the strongest evidence at the anonymous marker D2S125 on chromosome 2q, and they were able to exclude the existence of a single major locus for NIDDM thro u g h o u t most of the genome. Mahtani et al. (39) failed to find compelling evidence for linkage anywhere in the genome with their complete sample. However, when they restricted attention to the six families with the lowest mean 30-min insulin level during an OGTT among the affected individuals, they did find evidence for linkage to the MODY3 region of chromosome 12q.
Rationale for a whole genome search
We have chosen to carry out a whole genome search for genes for NIDDM with linkage analysis using a map with an average resolution of 10 cM. This approach has the advantage of assaying the entire genome. The alternative candidate-gene a p p roach is attractive because of its low cost. However, an approach based solely on candidate genes is unlikely to detect all or even most NIDDM susceptibility loci, because many such genes may be novel with no presently known homologs.
Once a candidate region is identified by linkage analysis, association analysis to identify linkage disequilibrium may help narro w the region of interest. At that stage, identification of candidate genes within the re g i o n may prove useful, an approach that has been called positional candidate cloning (62) .
Approaches to maximize power to detect linkage
We have taken several steps intended to maximize power to detect NIDDM genes. First, we have restricted family ascert a i nment to probands with the relatively early age of diagnosis of clinical diabetes of 35-60 years, because NIDDM is more stro n g l y familial in relatives of early-onset pro b a n d s (18) and environmental factors are likely to have greater effect at older ages.
Second, we have chosen a sampling design and analytic approach based on ASPs. Compared with the alternative of extended pedigrees, ASPs are easier to a s c e rtain. Furt h e rm o re, analysis of ASPs does not re q u i re ad hoc specification of mode of inheritance. Instead, allele sharing between affected siblings is compared with expectations assuming no linkage, so that excess allele sharing suggests linkage.
T h i rd, we have sought to minimize the number of families in which both pare n t s a re affected with NIDDM. Although such bilineal families can provide linkage information, for most genetic models, linkage i n f o rmation is substantially less than that p rovided by families with no affected pare n t s or with one affected parent (63) . To minimize bilineality, we gave pre f e rence to families with living parents and to those families in which one or both parents had lived a long life without known diabetes. Despite these eff o rts, it is likely that some of our families are bilineal, because only 42 parents in 577 families were available for a study visit, and because in one-sixth of the FUSION study families, neither parent had lived past the age of 61 years without known diabetes.
F o u rth, we sought to avoid families with IDDM. Our decision was based on a wish to minimize heterogeneity of the clinical phenotype. During the natural course of NIDDM, the endogenous insulin secre t i o n diminishes, often leading to a re q u i re m e n t for exogenous insulin (64, 65) . This situation can make it difficult to distinguish NIDDM f rom adult-onset IDDM, especially with the c u rrent trend in NIDDM therapy toward m o re aggressive treatment with insulin (66) . The magnitude of the problem is suggested by results from the Second National Health and Nutrition Examination Surv e y (NHANES II), in which 7.4% of all diabetic patients were classified as having adult-onset IDDM (67) . We have carefully phenotyped a ffected individuals to identify those with likely IDDM. We used a low serum C-peptide level as a marker for low endogenous insulin secretion, and antibodies to GAD as a marker for immune process, suggesting p robable adult-onset IDDM. While other markers such as ICA and ICA512 antibodies may be less prevalent in older-onset IDDM, GAD antibody prevalence remains high in this age-group (68) . Together with thoro u g h medical re c o rd re v i e w, we classified 43 a ffected individuals in 39 FUSION families as p robable adult-onset IDDM. These families will be excluded from most analyses.
Fifth, we have carried out extensive phenotyping in the families. Many cases of NIDDM are asymptomatic and can only be detected by testing glucose tolerance. In Finland, the pro p o rtion of such undetected cases of all NIDDM patients is estimated to be 25-40% (69, 70) . Thus, as much as possible, family members of NIDDM patients w e re tested for glucose tolerance to confirm their glucose tolerance status. In addition, we carried out FSIGTs together with Minimal Model analysis (22,71) in the unaff e c t e d o ffspring and spouses of the index case or of an affected sibling in a subset of our families. This approach estimates the individual physiological functions that determine the ability of the human organism to dispose of carbohydrate nutrients, including insulin s e n s i t i v i t y, glucose effectiveness, and acute insulin response. Knowledge of these phenotypes provides the opportunity to separately map the responsible genes for each component of the glucose homeostatic system. Perhaps even more important is that it will provide information to help assess the roles of the genes localized by linkage analysis of NIDDM.
In our study, we found that the nonaffected offspring of NIDDM patients were m o re insulin sensitive than nonaff e c t e d spouses of the patients. There are several factors that may explain this finding. 1) Insulin sensitivity may decline with age (72), although not all studies show the association between biological age and insulin re s i stance when body weight and distribution of body fat has been taken into account (73, 74) . In the study by Chen et al. (72) , 57-to 82-year-old men had 63% lower insulin sensitivity than 18-to 36-year-old men matched for body weight and fasting glucose. In our study, male spouses had 37% lower insulin sensitivity, and female spouses 19% lower insulin sensitivity, than the offspring. 2) Obesity, abdominal obesity, and h y p e rglycemia are all well-known factors associated with insulin resistance (73, 75) . The spouses in our study were more obese than the offspring. Also, waist-to-hip ratios w e re higher, indicating a higher degree of abdominal obesity in spouses. More o v e r, spouses had slightly higher glucose values in the OGTT than their offspring. 3) Of the spouses, 25% re p o rted diabetes in their parents, suggesting a genetic predisposition to diabetes in some of the nonaffected spouses, with the pro p o rtion being appro x i m a t e l y the same as expected in the Finnish general population (49, 69, 70) .
Sixth, we have sampled a large number of ASP families. Our power calculations suggest that even 400 ASPs typed on a 10-cM map provide 82% power to detect a gene that confers a 1.8-fold excess risk to siblings of affected individuals at an LOD score of 3.0 (32). Even for a 1.4-fold excess risk, there is 81% power to detect genes at an LOD score of 1.0. Our large sample should also pro v i d e an excellent basis for carrying out confirm ation studies for linkage or association re s u l t s re p o rted by other gro u p s .
Limitations of the sampling design
Several of the choices we made to maximize power to detect NIDDM genes may have limited the set of NIDDM genes that we will be able to detect. By choosing a re latively homogeneous population such as the Finns, we may have limited the number of segregating genes available for detection. By selecting early diagnosed probands primarily from the NHDR, we are pre f e re ntially sampling more severely aff e c t e d individuals. If the genes for early, more s e v e re NIDDM are diff e rent from those for l a t e r, less severe disease, we will have i n c reased our power to detect one set of genes at the expense of the other. We believe that increased power to identify a subset of NIDDM genes more than off s e t s loss of the theoretical opportunity to detect all such genes. By requiring the presence of an ASP, we might be identifying genes for familial NIDDM rather than for all NIDDM. H o w e v e r, given the high degree of familiality of NIDDM in all populations that have been studied, this problem does not appear to be significant, particularly because genes for familial disease often turn out to have a m o re general importance (76) (77) (78) .
Several of these choices also made it m o re difficult to identify and re c ruit acceptable families. In Finland, only 3% of symptomatic NIDDM patients have their disease onset before the age of 40 years, and only 37% have it before the age of 60 years (64,79). Our re q u i rement for a second a ffected sibling and zero or only one pare n t known to be affected, and our exclusion of families with IDDM, further restricted the pool of suitable families. Thus, scre e n i n g m o re than 22,000 NIDDM patients re s u l t e d in only about 1,550 individuals (7%) meeting our study criteria. Even a lower pro p o rtion of suitable families was re p o rted fro m the English study of Cook et al. (80) , in which primary screening criteria were less stringent than ours. Their conclusion was to initiate large-scale collaborative multicenter studies to collect the family material necess a ry for the study of susceptibility genes for NIDDM. In contrast, the FUSION study has demonstrated that it is feasible, although not easy, to collect a large number of ASP families with NIDDM within one population even after applying careful selection criteria.
Future directions
Given our success in family collection and phenotypic analysis in the FUSION study, we are moving forw a rd with FUSION 2, in which we hope both to extend our curre n t FUSION families and to obtain additional families. In all our current FUSION families, we will type unaffected siblings to allow more accurate inference of identity by descent in the ASPs for purposes of linkage analysis. In our current FUSION nuclear families, we will sample a spouse and offspring of one of the affected siblings for purposes of haplotype determination and linkage disequilibrium mapping. We also plan to identify and sample a second set of Finnish families as a replication set to allow us to immediately test interesting chro m osomal regions in a second, comparable set of families. In addition, we will obtain a sample of pare n t -o ffspring trios, in which the offspring is affected with NIDDM and the parents are living, to allow family-based association studies (81) .
Even given a large initial sample of families and a second replication sample, detection of NIDDM susceptibility genes by linkage analysis will depend on a combination of hard work and good luck. Most critical will be the magnitude of the effect of the various susceptibility genes on disease risk. With a combined sample of perh a p s 800 ASPs, we would have 69% power to detect a locus with the impact estimated by Hanis et al. (38) for their chromosome 2q locus at an LOD score of 3.0. However, for a locus that confers a 1.2-fold excess risk to siblings, even 800 ASPs would be expected to provide an LOD score of only 1.59 (32) . Thus, in genetic studies of NIDDM and other common, complex genetic diseases, sharing results with other workers in the field and combining data from comparable samples will be critical to our success in identifying disease susceptibility genes.
